GAITHERSBURG – AstraZeneca said on Monday it will invest $2 billion to expand its manufacturing footprint in Maryland, including a major expansion of its biologics facility in Frederick and construction of a new clinical manufacturing site in Gaithersburg. The investment will support 2,600 jobs across the two sites, including 300 highly skilled roles, retention of…
Tag: AstraZeneca
AstraZeneca to begin $4.5 billion Virginia facility expands U.S. drug manufacturing
The manufacturing facility is expected to create 3,600 jobs WILMINGTON: AstraZeneca is investing $4.5 billion in its new manufacturing facility in Virginia, a proposed increase of $500 million to support the enhanced manufacturing capability of a broader range of medicines including cancer treatments. This is part of the historic $50 billion investment announced in July…
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
LONDON: AstraZeneca today announced $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America…
AstraZeneca, CSPC Pharmaceuticals form AI-driven research partnership
LONDON: AstraZeneca has entered a strategic research collaboration with China-based CSPC Pharmaceuticals Group Limited to accelerate the discovery of novel oral therapies using artificial intelligence. The partnership will focus on identifying and developing pre-clinical candidates for chronic diseases, including a small-molecule oral therapy for immunological conditions. The research will leverage CSPC’s AI-powered drug discovery platform, which analyzes…
AstraZeneca signs definitive agreement to acquire EsoBiotec for $1 billion
LONDON: AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer many more patients access to transformative cell therapy treatments delivered in just minutes rather…
AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
LONDON: AstraZeneca today announced $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the end of 2026. This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs contributing to the growth of the US economy. AstraZeneca’s expanding footprint in the…
AstraZeneca announces $1.5 billion investment in Singapore manufacturing
LONDON: AstraZeneca has unveiled plans to construct a state-of-the-art manufacturing facility in Singapore, dedicated to the production of antibody drug conjugates (ADCs). This $1.5 billion venture marks the company’s first foray into manufacturing within Singapore and represents a significant step in enhancing the global supply of its ADC portfolio. ADCs, which are at the forefront…
EU Panel endorses AstraZeneca’s breast cancer drug Truqap
LONDON: The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AstraZeneca’s drug Truqap, in combination with Faslodex, for treating certain advanced breast cancer cases. The positive opinion is based on the CAPItello-291 Phase III trial results, which showed a 50% reduction in disease progression or death compared…
Angle plc signs new commercial agreement with AstraZeneca
LONDON: ANGLE plc (AIM:AGL), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology has signed a supplier agreement with the global biopharmaceutical company, AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE’s existing DNA damage response (“DDR”) assay for the detection of…
AstraZeneca to acquire Fusion Pharmaceuticals in a $ 2.0 billion deal
LONDON: AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. RCs…
AstraZeneca enters definitive agreement to acquire Amolyt Pharma for $1.05 billion
AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. Under the terms of the agreement, AstraZeneca will acquire all of Amolyt Pharma’s outstanding shares for a total consideration of up to $1.05 billion, on a cash and debt free basis….
AstraZeneca reports strong growth in 2023 despite COVID-19 challenges
AstraZeneca, a global biopharmaceutical company, announced its financial results for the full year 2023, showing a 6% increase in total revenue and a 15% increase in core earnings per share. The company’s total revenue reached $45,811 million, up from $43,075 million in 2022, despite a decline of $3,736 million from COVID-19 medicines. Excluding COVID-19 medicines,…